Table 1.

Baseline Patient and Disease Characteristics

Characteristic	Number (%)
No. of patients	28
Disease type - no. (%)
DLBCL	17 (61)
HGBCL	4 (14)
Transformed indolent B cell lymphoma	7 (25)
Age
Median (range) - yr.	65 (48 – 86)
≥65 yr. - no. (%)	13 (46)
Male sex - no. (%)	15 (54)
Prior therapies - no. (%)
Primary refractory disease	24 (86)
Refractory to last line of therapy pre-apheresis	25 (89)
Prior autologous SCT	3 (11)
Prior CD19 directed therapy	3 (11)
Prior lines of therapy
Median (range)	1 (1 – 6)
≥2 prior lines of therapy - no. (%)	11 (39)
Genomics*
Double-hit	7 (30)
TP53 mutated	7 (30)
Double-hit or TP53 mutated	12 (52)
Bridging therapy - no. (%)	25 (89)
Chemotherapy	19 (68)
Radiation	6 (21)
Metabolic tumor volume, median (range) - ml
At enrollment	51.8 (0.5 – 831.9)
At lymphodepleting chemotherapy**	37.1 (0 – 413.3)
Median tumor burden at lymphodepleting chemotherapy¶ (range) - mm2	1,430 (0 – 8,611)
LDH > ULN at enrollment - no. (%)	14 (50)
Median LDH (range), U/l	349 (152 – 3,754)
LDH > ULN at lymphodepleting chemotherapy - no. (%)	11 (39)
Median LDH (range), U/l	181 (141 – 1,073)
CRP at lymphodepleting chemotherapy
Median CRP (range), mg/dL	0.30 (0.07 – 18.70)

Abbreviations: DLBCL, diffuse large B-cell lymphoma; HGBCL, high grade B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; SCT, stem cell transplant; SPD: sum of the products of diameters; LDH: lactate dehydrogenase; ULN, upper limit of normal; CRP, C-reactive protein.

^*Available in 23 patients.

^**Restaged after bridging (if administered) and immediately prior to lymphodepleting chemotherapy and prior to CAR T cell infusion.

^¶Tumor burden was determined on the basis of the sum of product diameters of the target lesions, according to the Cheson criteria⁴¹.